Anti myadm

For Western blotting, anti-β-actin, anti-CyclinD1, anti-CDK2 (Cell Signaling, Danvers, MA, USA), anti-SMAD4, anti-p21/Cip1 (Abcam, Cambridge, MA, USA), anti-KLF4 (Proteintech, Wuhan, Hubei, China), anti-proliferating cell nuclear antigen (anti-PCNA) (Proteintech, Wuhan, Hubei, China), and anti-myeloid-associated differentiation marker (anti-Myadm) (Novus, Littleton, CO, USA) antibodies were used as the primary antibodies. The signals were detected using the enhanced chemiluminescence detection method and were quantified by densitometry.

Cell immunofluorescence analyses were performed using anti-p21(Abcam, Cambridge, MA, US), and anti-KLF4 (Proteintech, Wuhan, China) as primary antibodies, followed by FITC (green fluorescence, Chemicon, Temecula, CA, USA)-conjugated secondary antibodies and visualized by Cellomics array scan (ArrayScan VTI HCS Reader; Cellomics). The nuclei were visualized by DAPI staining.
For the tissue immunofluorescence staining, sections were incubated with anti-SM-α actin (SMA, 1:50, Santa Cruz, Texas, USA) and anti-Myadm (1:50, Novus, Littleton, CO, USA) antibodies, followed by fluorescein-conjugated secondary antibodies (1:300 dilution). The cell nuclei were stained with DAPI.